Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

Clinical trial NCT04745910 · COMPLETED

Trial details

NCT number: NCT04745910
Sponsor: M.D. Anderson Cancer Center
Status: COMPLETED
Phase: Phase 4
Study type: INTERVENTIONAL

Hematopoietic and Lymphoid Cell Neoplasm Malignant Solid Neoplasm Tumor Lysis Syndrome

Start date: 2022-04-05
Primary completion: 2026-04-27
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.